BioNTech SE
Innovative immunotherapies fighting diseases
- B2B
- B2G
- Has physical offices
- Publicly traded
- Healthtech
- Sales-led purchase
About BioNTech SE
Development of novel immunotherapies leveraging mRNA technology to combat cancer and infectious diseases, improving global health outcomes.
Key facts
- Industry
- Biotechnology Research
- Company size
- 5,001–10,000 employees
- Headquarters
- Mainz, Rhineland-Palatinate, Germany
- Founded
- 2008
- Revenue
- $56.3M – $445MTamtam estimate
- Website
- biontech.com
- linkedin.com/company/biontech-se
Jobs at BioNTech SE
- Manager Global Quality Systems - Pharma Compliance
- Director Manufacturing Sciences & Technology
- Associate Director, Procurement - US Commercial & Medical
- Director Program & Production Procurement CDMO / CMO
- Senior Director External Manufacturing QA
- Manager GxP Compliance Management Mainz (m/w/d)
- (Associate Director) Senior Scientist Manufacturing global MS&T
- Associate Director, CMC Manufacturing Technologies
BioNTech SE in the news
- BioNTech stock after-hours at EUR 87.00: plus 0.29 percent
BioNTech's stock rose slightly while the company announced it will close German sites, impacting up to 1,860 jobs, as COVID-19 vaccine production shifts to Pfizer.
- BioNTech CEO sells 39,000 shares. BioNTech stock has a USD 126.00 average target
BioNTech CEO Ugur Sahin sold 39,000 shares amidst a significant Q2 2026 revenue decline and widened net loss, though analyst targets remain positive.
- Under a June 3 trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 34,000 and 32,000 shares.
BioNTech CEO Ugur Sahin sold 66,000 shares in September 2026 under a pre-arranged trading plan.
- BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial
BioNTech is initiating the Dareon-Rosetta35 clinical trial to test new cancer drugs for advanced small cell lung cancer, marking its entry into solid tumor treatment.
- BioNTech stock trades at EUR 86.05 after a revenue miss
BioNTech's stock dipped after missing revenue expectations, reporting a substantial loss, and reducing its full-year guidance, though analysts maintain a 'Moderate Buy' rating.
BioNTech SE at a glance
BioNTech SE is a B2B/B2G company in the Biotechnology Research industry, headquartered in Mainz, Rhineland-Palatinate, Germany.
BioNTech SE was founded in 2008.
BioNTech SE has 5,001–10,000 employees.
BioNTech SE's revenue is $56.3M – $445M (Tamtam estimate).
BioNTech SE is hiring: 8 recent open roles, including Manager Global Quality Systems - Pharma Compliance, Director Manufacturing Sciences & Technology, Associate Director, Procurement - US Commercial & Medical.
Selling to companies like BioNTech SE?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies